Addex Therapeutics Ltd

NasdaqCM:ADXN

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

💊 Pharmaceuticals

Location

Switzerland

Market Cap

USD 9.16 M

Share Price

USD 8.21

Avg Daily Volume

5,315

Change (1 day)

-2.96%

Change (1 year)

2.88%

Change (YTD)

17.29%

Addex Therapeutics Ltd EBIT for the Trailing 12 Months (TTM) ending December 31, 2024

Addex Therapeutics Ltd EBIT is NA for the Trailing 12 Months (TTM) ending December 31, 2024. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Addex Therapeutics Ltd EBIT for the Trailing 12 Months (TTM) ending December 31, 2022 was USD -21.92 M, a 32.79% change year over year.
Addex Therapeutics Ltd EBIT for the Trailing 12 Months (TTM) ending December 31, 2021 was USD -16.50 M, a 20.87% change year over year.
Addex Therapeutics Ltd EBIT for the Trailing 12 Months (TTM) ending December 31, 2020 was USD -13.65 M, a -8.28% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NasdaqCM: ADXN

Addex Therapeutics Ltd

CEO	Mr. Timothy Mark Dyer
IPO Date	Feb. 12, 2020
Location	Switzerland
Headquarters	Chemin des Mines, 9
Employees	2
Sector	🏥 Health Care
Industries Clinical Trials 💊 Drugstores & Retail Pharmacies 💊 Pharmaceuticals

Description

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.